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Abstract
Background: In this study, we investigated the mechanism(s) by which delta opioids induce their
potent activation of extracellular signal-regulated protein kinases (ERKs) in different cell lines
expressing the cloned δ -opioid receptor (δ -OR). While it has been known for some time that OR
stimulation leads to the phosphorylation of both ERK isoforms, the exact progression of events has
remained elusive.
Results: Our results indicate that the transphosphorylation of an endogenous epidermal growth
factor receptor (EGFR) in the human embryonic kidney (HEK-293) cell line does not occur when
co-expressed δ -ORs are stimulated by the δ -opioid agonist, D-Ser-Leu-enkephalin-Thr (DSLET).
Moreover, neither pre-incubation of cultures with the selective EGFR antagonist, AG1478, nor
down-regulation of the EGFR to a point where EGF could no longer activate ERKs had an inhibitory
effect on ERK activation by DSLET. These results appear to rule out any structural or catalytic role
for the EGFR in the δ -opioid-mediated MAPK cascade. To confirm these results, we used C6
glioma cells, a cell line devoid of the EGFR. In δ -OR-expressing C6 glioma cells, opioids produce a
robust phosphorylation of ERK 1 and 2, whereas EGF has no stimulatory effect. Furthermore,
antagonists to the RTKs that are endogenously expressed in C6 glioma cells (insulin receptor (IR)
and platelet-derived growth factor receptor (PDGFR)) were unable to reduce opioid-mediated
ERK activation.
Conclusion: Taken together, these data suggest that the transactivation of resident RTKs does
not appear to be required for OR-mediated ERK phosphorylation and that the tyrosine-
phosphorylated δ -OR, itself, is likely to act as its own signalling scaffold.
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Background
Opioid receptors (ORs), like many other G protein-cou-
pled receptors (GPCRs), are capable of signalling via the
family of mitogen activated protein kinases (MAPKs). It
has been postulated that activation of these kinases allows
GPCR agonists to modulate such diverse molecular events
as cell proliferation, differentiation, and survival [1]. To
date, all three cloned opioid receptor types (µ,δ , κ ) and
the closely related nociceptin receptor have demonstrated
the ability to signal through their heterotrimeric G pro-
teins (Gi or Go) to at least one type of MAPK [2–4].
Among the members of this family that are activated by
opioids, are the two extracellular signal-regulated protein
kinases (p44MAPK (ERK 1) and p42MAPK (ERK 2)) [5] and
the p38 protein kinase [3]. However, the precise mecha-
nism by which OR stimulation produces an increase in
MAPK activity is still unknown and under investigation.
While receptor, cell, and tissue-specific differences almost
certainly exist and appear to make any single mechanism
of ERK activation unlikely, certain generalities have begun
to emerge. For example, ERK activation by GPCRs is pre-
dominantly a Ras-dependent event, one that utilizes
many of the upstream protein intermediates (i.e. Shc,
Gab1, Grb2, mSOS, and MAPK kinase (MEK-1)) known
to be used by single-transmembrane receptor tyrosine ki-
nases (RTKs) like the epidermal growth factor receptor
(EGFR) (for a review see [6]). When ERKs are activated af-
ter EGFR stimulation, an essential event is the sequential
tyrosine phosphorylation of these intermediate proteins
and their binding to the tyrosine phosphorylated EGFR
before the GTP-loading of Ras. For the GPCR model, the
tyrosine kinase(s) involved and the site of this multi-pro-
tein complex formation is less clear. For a number of
GPCRs, including the lysophosphatidic acid (LPAR) [7],
β -adrenergic2 (β 2-AR) [8] and µ- and δ -OR receptors [9],
the activation of a non-receptor tyrosine kinase of the Src
or focal adhesion kinase (FAK) [10] families are involved.
However, the question of what plasma membrane-span-
ning protein serves as the scaffold for Shc binding and be-
yond remains to be answered.
Two possibilities have emerged as potential sites of tyro-
sine phosphorylation and subsequent scaffold building in
response to GPCR stimulation, which results in ERK acti-
vation: the GPCR, itself, or a co-expressed RTK (i.e. the
EGFR) that would act as a surrogate. We and others and
we have reported that µ- and δ -opioid receptors become
tyrosine phosphorylated after agonist-stimulation
[11,12]. Tyrosine phosphorylation of a membrane-bound
protein is an essential step in ERK activation, because it
creates SH2-binding domains that allow Shc and other
proteins to associate into a multi-protein signalling com-
plex. The mutation of one of the tyrosines (Y318F) in the
δ -OR or the presence of the Src inhibitor, PP1, significant-
ly reduces tyrosine phosphorylation of this receptor and
its ability to activate ERKs [11,13]. However, a small de-
gree of δ -OR agonist-mediated ERK activation remained
in cells expressing the Y318F mutant receptor, suggesting
that a second mechanism or an additional tyrosine could
be involved. These data suggest that the tyrosine phospho-
rylation of GPCRs may allow them to signal ERKs in the
absence of RTK or FAK phosphorylation by acting as their
own scaffolds.
However, the majority of the published studies have fo-
cused on the hypothesis that GPCRs must work in coop-
eration with RTKs (i.e. the EGFR) to produce ERK
activation. Studies by Daub et al., [7] and Luttrell et al.,
[14] have demonstrated that stimulation of LPAR (Gi/q-
coupled) and β 2-ARs (Gs-coupled), respectively, results in
the "transactivation /transphosphorylation" of co-ex-
pressed EGFRs. For example, both EPA and isoproterenol
increase the tyrosine phosphorylation of the EGFR, which
appears to be required for ERK activation since the pres-
ence of kinase-deficient EGFR mutants or the kinase in-
hibitor, AG1478, prevents both responses. It is
hypothesized that trans-tyrosine phosphorylation of the
EGFR creates protein phosphotyrosine binding sites that
act as a surrogate scaffold for ERK activation [7]. Since
ORs share many similarities with LPAR and β 2-ARs in the
way they activate the ERK pathway [9,15], we chose to ex-
amine whether RTK transactivation occurs and is a neces-
sary aspect of δ -opioid-mediated ERK activation.
Results
DSLET and EGF induce ERK phosphorylation in δ -OR-ex-
pressing HEK-293 cells
We have shown that δ -opioids increase the phosphoryla-
tion of ERKl/2 in HEK-293 cells when the mouse wild type
(WT) δ -OR is stably expressed [11,13]. The concentrations
required to observe DSLET-mediated ERK phosphoryla-
tion (EC50 = 10 nM; Figure 1a) are consistent with those
reported for other δ -OR-mediated events, including G
protein activation and adenylyl cyclase inhibition [16,17].
Moreover, no change in total ERK expression was ob-
served, concomitantly, with ERK phosphorylation in any
of our experiments (data not shown). Pretreating the cells
with PTX (100 ng/ml), or the specific δ -OR antagonist,
naltrindole (10 µM), completely blocked the DSEET-in-
duced increase in ERK phosphorylation (Figure 1b). These
results suggest that DSLET utilizes a Gi-coupled δ -OR to
stimulate ERK 1 and 2. We then took advantage of the
HEK-293 cell line's endogenous expression of the EGFR to
examine this receptor's ability to activate ERKs. Similar to
DSLET, EGF (5 ng/ml) produces a robust activation of
ERKs in δ -OR-expressing HEK-293 cells after a 5 minute
treatment (Figure 2a). PTX did not attenuate EGF-mediat-
ed ERK activation (Figure 2a), although this response was
completely blocked by the EGFR kinase inhibitor,BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/5
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AG1478 (1 µM) (Figure 2a). Conversely, DSLET-induced
ERK activation was unaffected by AG1478, suggesting that
different tyrosine kinases are involved in opioid- and EGF-
dependent MAPK activity (Figure 2b). DSLET-mediated
ERK activation was significantly inhibited by the Src ki-
nase inhibitor, PP1 (10 µM) (Figure 3). PP1 also had a sig-
nificant inhibitory (75% reduction) effect on MAPK
activation by EGF (Figure 3).
DSLET-induced ERK activation does not produce hyper-
phosphorylation of the EGFR
Our next experiments were designed to examine whether
the EGFR becomes tyrosine phosphorylated during ERK
activation by DSLET. As stated in the introduction, several
GPCRs (including the EPAR, β 2-AR, and substance P (SP-
R)) [14,18–20] increase EGFR phosphorylation during
the course of ERK activation, and it is believed, that in
these instances, this event is an initial step in the progres-
sion of the MAPK cascade. Our laboratory has previously
reported [11,13] that 5-opioids induce tyrosine phospho-
rylation of the δ -OR, and it appears that this is catalyzed
by the non-receptor tyrosine kinase Src. However,
transphosphorylation of the EGFR after OR activation has
not been reported. WT-δ -OR-expressing HEK-293 cells
were exposed to increasing concentrations of either DS-
LET (1–1000 nM) or EGF (0.1–100 ng/ml) for five min-
utes to induce ERK activation. As stated earlier, either
DSLET or EGF increased the appearance of phosphorylat-
ed ERK in a time and concentration dependent manner. A
portion of the lysates used to measure ERK activation was
used to immunoprecipitate the EGFR or δ -OR to deter-
mine their degree of tyrosine phosphorylation. After im-
munoprecipitation of the FLAG-tagged δ -OR or the EGFR
with the appropriate antibodies, we found that only DS-
LET induced tyrosine phosphorylation of the δ -OR,
whereas only EGF potentiated EGFR phosphorylation
(Figure 4). 1 µM DSLET-induced tyrosine phosphoryla-
Figure 1
Western blots characterizing ERK phosphorylation by
DSLET. (1A) HEK-δ -OR cells were serum-starved overnight
prior to exposure to DSLET (1 pM – 1 µM for 5 minutes).
After DSLET exposure, cell lysates were prepared and ERK
phosphorylation was determined by SDS PAGE, followed by
immunoblotting of proteins onto nitrocellulose. Immunopos-
itive bands correspond to α -tubulin, and the phosphorylated
forms of ERK 1 and ERK 2. (1B) Inhibitory effects of naltrin-
dole (10 µM) or PTX (100 ng/ml) on DSLET-stimulated ERK
phosphorylation. Naltrindole was added 60 minutes prior to
DSLET, while PTX was added 18 hours before the δ -OR ago-
nist. After DSLET exposure, cell lysates were prepared and
ERK phosphorylation was determined by SDS PAGE, fol-
lowed by immunoblotting of proteins onto nitrocellulose.
Immunopositive bands correspond to the phosphorylated
forms of ERK 1 and ERK 2. The immunoblots are represent-
ative of an experiment that was repeated three times.
Figure 2
Western blots showing the effect of AG 1478 on ERK phos-
phorylation by EGF (2A) or DSLET (2B). (2A) HEK-δ -OR
cells were serum-starved overnight prior to exposure to
EGF (5 ng/ml for 5 minutes) in the presence or absence of
PTX pretreatment (100 ng/ml; overnight) or AG1478 (1 µM;
60 minutes prior) . After DSLET exposure, cell lysates were
prepared and ERK phosphorylation was determined by SDS
PAGE, followed by immunoblotting of proteins onto nitro-
cellulose. Immunopositive bands correspond to α -tubulin,
ERK 1, and ERK 2. (2B) AG1478 has no effect on DSLET-
stimulated ERK phosphorylation. AG1478 (1 µM) was added
60 minutes prior to DSLET (1 pM – 1 µM for 5 minutes).
After DSLET exposure, cell lysates were prepared and ERK
phosphorylation was determined by SDS PAGE, followed by
immunoblotting of proteins onto nitrocellulose. Immunopos-
itive bands correspond to α -tubulin, ERK 1 and ERK 2. The
immunoblots are representative of an experiment that was
repeated three times.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/5
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tion of the δ -OR was inhibited by naltrindole, PP1, but
not by AG1478 (Figure 5). These results suggest that trans-
activation of the EGFR does not play a role in δ -OR phos-
phorylation or ERK activation by δ -opioids.
Determining whether a co-expressed RTK is structurally 
necessary for δ -OR-mediated ERK activation
EGFR down-regulation does not affect DSLET-mediated ERK activa-
tion in HEK-293 cells
Despite the lack of direct evidence that DSLET induces the
transactivation of co-expressed RTKs, it is possible that the
EGFR, in some way, contributes to ERK activation by opi-
oids. It is possible that RTKs and GPCRs share important
protein intermediates that are required during ERK activa-
tion. Therefore, we wished to determine what effects the
down-regulation of the EGFR would have on ERK signal-
ling via the δ -OR. HEK-293 cells expressing the WT-δ -OR
were exposed to EGF (100 ng/ml) for 24 hours in order to
down-regulate and desensitize the endogenous EGFR. Af-
ter chronic EGF treatment, the cultures were washed with
serum-free media and then exposed acutely (5 minutes)
to either EGF (10 ng/ml) or DSLET (1 µM) to stimulate
ERK phosphorylation. In EGF pre-treated cultures, acute
EGF (10 ng/ml) was unable to increase the expression of
phospho-ERKs compared to media-exposed controls (Fig-
ure 6). This lack of response appears to be due to the
down-regulation of EGFRs from these cells as confirmed
by immunoblots using the anti-EGFR antibody (data not
shown). However, DSLET-mediated ERK activation was
unaltered in identically pretreated cultures.
In cells pretreated with DSLET (10 µM; 24 hours) to in-
duce down-regulation of δ -ORs [21], DSLET (1 µM) was
no longer able to activate the ERK cascade, but the ERK re-
sponse to acute EGF (10 ng/ml) was unchanged com-
pared to medium-treated controls (Figure 6). These results
indicate that a reduction in the function and density of en-
dogenous EGFRs has little effect on opioid-mediated
MAPK cascades, and suggests that the enzyme cascades
that control δ -OR- and EGFR-mediated ERK activation are
separate.
DSLET activates ERK even in a cell line devoid of the EGFR
C6 glioma cells have been used as host cells for the trans-
fection of several GPCR types, and have the advantage of
expressing high levels of ERK, while being devoid of the
EGFR. In C6 glioma cells that express the mouse δ -OR,
DSLET produced a concentration-dependent increase in
the appearance of phospho-ERK 1 and 2. DSLET-mediat-
ed ERK activation in C6-δ -OR cells was completely inhib-
ited by either pre-treatment with PTX or naltrindole (data
not shown). In contrast, EGF was unable to elicit ERK ac-
Figure 3
Western blot characterizing the effect of PP1 on ERK phos-
phorylation by EGF (5 ng/ml for 5 minutes) or DSLET (1 µM
for 5 minutes). HEK-δ -OR cells were serum-starved over-
night prior to exposure to EGF or DSLET. In some instances,
cells were exposed to PP1 (10 µM) for 60 minutes prior to
DSLET or EGF. After agonist exposure, cell lysates were pre-
pared and ERK phosphorylation was determined by SDS
PAGE, followed by immunoblotting of proteins onto nitro-
cellulose. Immunopositive bands correspond to α -tubulin,
ERK 1, and ERK 2. The immunoblot is representative of an
experiment that was repeated three times.
Figure 4
Western blots showing the effect of DSLET or EGF on tyro-
sine phosphorylation of the δ -OR or the EGFR. HEK-δ -OR
cells were serum-starved overnight prior to exposure to
EGF (0.1 – 100 ng/ml for 5 minutes) or DSLET (10 nM-10 µM
for 5 minutes). After agonist exposure, cell lysates were pre-
pared and the δ -OR or the EGFR was immunoprecipitated as
described in the methods section using the appropriate anti-
bodies. Tyrosine phosphorylation of these receptors was
determined by SDS PAGE, followed by immunoblotting of
proteins onto nitrocellulose. Immunopositive bands corre-
spond to the tyrosine-phosphorylated forms of the δ -OR
(upper panel) or the EGFR (lower panel). The immunoblots
are representative of an experiment that was repeated three
times.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/5
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tivation, at any concentration tested, up to 1 µM (Figure
7). Furthermore, the EGFR antagonist, AG1478, had no
effect on DSLET-mediated ERK activation, which elimi-
nated the possibility that these antagonists produced non-
specific, inhibitory effects (Figure 7).
Potential of endogenously expressed insulin receptors (IR) and PDG-
FR to act as surrogate protein scaffolds during ERK activation by δ -
opioids
However, C6 glioma cells express additional RTKs includ-
ing insulin (IR) and platelet-derived growth factor (PDG-
FR) receptors. It is possible that these sites can be used as
surrogate scaffold proteins during ERK activation, and we
explored the possibility that δ -opioids induce the
transphosphorylation of these two RTKs. At concentra-
tions of 10 µM, neither DSLET, DADLE, nor DPDPE were
found to increase the tyrosine phosphorylation of the IR
or the PDGFR, whereas insulin (100 ng/ml) or PDGF (50
ng/ml) induced significant tyrosine phosphorylation of
these sites (Figure 8). Moreover, we pre-treated C6-δ -OR
cells with the IR antagonist, hydroxy-2-napthalenylmeth-
ylphosphonic acid-tris acetoxymethylester (HNMPA-
(AM)3; 100 µM), or the PDGFR antagonist, (tyrosphostin
9; 100 µM) before the addition of DSLET (1 µM). Despite
the presence of these catalytic RTK inhibitors, δ -opioid-
mediated ERK activation was not significantly altered in
comparison to untreated cultures (Figure 9). Furthermore,
immunoprecipitation of the δ -OR, followed by immuno-
blotting using anti-phosphotyrosine antibodies, revealed
that these inhibitors did not attenuate tyrosine phospho-
rylation of δ -ORs after DSLET treatment (Figure 9). The re-
sults presented, herein, strongly suggest that
transactivation of RTKs does not make a significant contri-
bution to DSLET-induced ERK activation in at least two
different cell lines.
Discussion
With the first evidence that GPCRs could signal via the
MAPK cascade, many investigators have looked for a com-
mon mechanism of activation that could be applied
across receptor types. Unlike the better understood mech-
anism whereby single-transmembrane RTKs (e.g. EGFR,
IR, or PDGFR) stimulate ERKs [22,23], no single sequence
of events appears to hold among GPCRs, even when they
Figure 5
Western blot characterizing the effect of naltrindole, PP1, or
AG1478 on tyrosine phosphorylation of the δ -OR by DSLET
(1 µM for 5 minutes). HEK-δ -OR cells were serum-starved
overnight prior to exposure to DSLET. In some instances,
cells were exposed to PP1 (10 µM) or AG1478 (10 µM) for
60 minutes prior to DSLET. After agonist exposure, cell
lysates were prepared and the δ -OR was immunoprecipi-
tated as described in the methods section using the anti-
FLAG antibody. Tyrosine phosphorylation of the δ -OR was
determined by SDS PAGE, followed by immunoblotting of
proteins onto nitrocellulose. Immunopositive bands corre-
spond to the tyrosine-phosphorylated forms of the δ -OR.
The immunoblot is representative of an experiment that was
repeated three times.
Figure 6
Effect of δ -OR or EGFR down-regulation on ERK phosphor-
ylation by acute exposure to DSLET or EGF. HEK-δ -OR cells
were serum-starved overnight prior to exposure to DSLET
(10 µM for 24 hours) or EGF (100 ng/ml for 24 hours) to
induce receptor down-regulation. After chronic agonist pre-
treatment, cell monolayers were washed once with fresh
media and exposed, acutely, to either DSLET (1 µM for 5
minutes) or EGF (10 ng/ml for 5 minutes). After acute ago-
nist exposure, cell lysates were prepared and ERK phosphor-
ylation was determined by SDS PAGE, followed by
immunoblotting of proteins onto nitrocellulose. PhosphoERK
-immunopositive bands were quantified using the MCID sys-
tem. Band intensities are expressed graphically (hatched
bars) as: grain density ×  band area - [region of detection
(ROD)] ×  pixel. Data points represent the mean ± SEM of
three experiments. *p ≤  0.05 compared to untreated samples
and **p ≤  0.01 compared to untreated samples as determined
by ANOVA and the Tukey post-hoc test.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/5
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are expressed in the same cell line. For instance, studies
from two laboratories reported marked differences in the
way the β 2-adrenergic receptor (β 2-AR) activates ERK 1
and 2 in HEK-293 cells. In one study, the β 2-AR activates
ERK through it's coupling to a PTX-sensitive Gi protein
and subsequent Ras activation [24], while, in another,
ERK phosphorylation occurred in a PTX-independent and
a Gs- and cAMP-dependent fashion [25]. Furthermore,
these studies indicate that the same receptor may activate
ERKs via one mechanism when it is endogenously ex-
pressed and via another when it is transfected into a cell
line [25].
Despite numerous reported differences, it does appear
that diverse GPCRs share common mechanistic themes
during ERK stimulation, including the tyrosine-phospho-
rylation of Shc and its complexing with Grb2, mSOS re-
cruitment, the GTP-loading of Ras, and Raf-1 activation
leading to MEK-1 phosphorylation [1]. However, the pro-
gression of each of these downstream events after GPCR
stimulation depends first on the tyrosine phosphorylation
of a membrane-bound protein that will be used as a scaf-
fold, which will bind the other proteins (e.g. Shc, Grb2,
Gab1, mSOS.... etc...) [7]. Moreover, the exact identity of
the tyrosine kinase(s) involved in this initial step appears
to vary among receptor types, with RTKs, non-receptor
protein tyrosine kinases (PTKs), or FAKs being involved in
particular instances [26].
In this report, we questioned whether the EGFR acts as a
surrogate scaffold during ERK activation through the δ -
OR, as it appears to do for several other GPCRs [7]. To act
as a surrogate-binding site for complex formation, the lit-
erature states that this protein must first become tyrosine-
phosphorylated [7]. Tyrosine phosphorylation of the
EGFR is apparent after agonist stimulation of the α 2-AR
(COS-7), β 2-AR (COS-7), insulin-like growth factor (IGF-
1; COS-7), substance P, and the lysophosphatidic acid re-
ceptor (LPAR) [7]. In addition, each of the aforemen-
tioned ligands also increases ERK phosphorylation when
Figure 7
ERK phosphorylation by DSLET (filled squares) or EGF (open
triangles) in C6 glioma cells stably-expressing the δ -OR. C6-
δ -OR cells were serum-starved overnight prior to exposure
to EGF (0.1 nM – 1 µM for 5 minutes) or DSLET (0.1 nM – 1
µM for 5 minutes). In some instances, DSLET-mediated ERK
phosphorylation was performed in cells pre-treated with
AG1478 (1 µM; filled circles) 60 minutes prior to DSLET.
After agonist exposure, cell lysates were prepared and ERK
phosphorylation was determined by SDS PAGE, followed by
immunoblotting of proteins onto nitrocellulose. PhosphoERK
-immunopositive bands were quantified using the MCID sys-
tem. Band intensities are expressed graphically as: grain den-
sity ×  band area - [region of detection (ROD)] ×  pixel. Data
points represent the mean ± SEM of three experiments.
Figure 8
Effect of δ -OR agonists, insulin, or PDGF on tyrosine phos-
phorylation of the insulin receptor or the PDGF receptor.
C6-δ -OR cells were serum-starved overnight prior to expo-
sure to DADEE (10 mM), DPDPE (10 mM), DSLET (10 mM),
insulin (100 ng/ml), or PDGF (50 mg/ml) for 5 minutes. After
agonist exposure, cell lysates were prepared and the IR or
the PDGFR was immunoprecipitated as described in the
methods section using the appropriate antibodies. Tyrosine
phosphorylation of these receptors was determined by SDS
PAGE, followed by immunoblotting of proteins onto nitro-
cellulose. Immunopositive bands correspond to the tyrosine-
phosphorylated forms of the IR (open bars) or the PDGF
(hatched bars). Phosphotyrosine bands were quantified using
the MCID system. Phosphotyrosine band intensities are
expressed graphically as: grain density ×  band area - [region
of detection (ROD)] ×  pixel. Data points represent the mean
± SEM of three experiments. *p  ≤  0.05 compared to
untreated samples as determined by ANOVA and the Tukey
post-hoc test.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/5
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the proper receptor is expressed in these cell lines. ERK ac-
tivation and EGFR phosphorylation via each of these re-
ceptors was inhibited by prior exposure to the EGFR
kinase inhibitor, AG1478.
However, the Src inhibitor, PP1 or the expression of a
dominant-negative Src mutant, will reduce GPCR-mediat-
ed transphosphorylation of the EGFR and GPCR-mediat-
ed ERK activation to varying degrees (partial to total),
suggesting that at least two different tyrosine kinases can
be involved [18]. Src was found to co-immunoprecipitate
with the phosphorylated EGFR in COS-7 cells exposed to
either LPA or EGF [14]. These authors reported that the
autophosphorylation of Y350 in the EGFR does not occur
after LPA exposure, suggesting that c-Src is the principal ty-
rosine kinase in this instance and not the EGFR's intrinsic
tyrosine kinase. Src has also been found to co-immuno-
precipitate with the agonist-stimulated β 2-AR during the
period of ERK activation [8]. Our previous work [11,13]
suggested that a Src-like protein tyrosine kinase was pri-
marily responsible for tyrosine phosphorylation of the δ -
OR and ERK activation induced by DTLET when the recep-
tor was expressed in CHO or HEK-293 cells, because both
responses were blocked by the presence of 50 µM PP1. The
seemingly dominant role of Src in opioid-mediated ERK
stimulation is strengthened in the present report because
of considerable evidence that the EGFR antagonist,
AG1478, was unable to reduce DSLET-mediated ERK acti-
vation. This suggests that the EGFR has minimal, if any,
involvement in the opioid-activated ERK cascade. It is
possible, that the dual coupling of the LPAR to both in-
hibitory (Gi) and stimulatory (G12/13 and Gq) G proteins
is a reason for these differences.
In this report, we have presented considerable evidence
that δ -ORs and EGFRs activate ERKs, independently, with-
out the need for transphosphorylation of a co-expressed
RTK. We used C6 glioma cells, transfected to stably ex-
press the mouse δ -OR, to examine ERK activation by δ -
opioids in a line that does not express the EGFR to con-
firm our results obtained in the receptor down-regulation
experiments. We observed that DSLET activated p42mapk
and p44mapk very robustly in this cell line. C6 glioma cells
do express growth factor receptors that bind PDGF and in-
sulin. However, neither of these proteins has been report-
ed to act as a surrogate scaffold during ERK activation by
non-opioid GPCRs [27]. In the present report, DSLET-me-
diated ERK phosphorylation was unaltered by the pres-
ence of the IR or PDGFR antagonists, HNMPA-(AM)3 and
tyrosphostin 9, respectively. It is probable that the δ -OR in
C6 glioma cells also acts as its own platform for the bind-
ing of Shc, etc., since the δ -OR also undergoes agonist-me-
diated tyrosine phosphorylation in this particular cell line
(Kramer et al., unpublished observations), similar to what
we previously reported for the δ -OR expressed in Chinese
hamster ovary or HEK-293 cells [11,13]. Thus, in at least
two different cell lines, HEK-293 and C6 glioma, we have
significant evidence that transactivation of an endog-
enously expressed RTK is not required for ERK activation
through opioid receptors.
While the EGFR does not appear to be phosphorylated
during DSLET-mediated ERK activation, it is possible that
the EGFR is somehow involved in this response when it is
present. Buist et al., [27] reported that endogenously-ex-
pressed LPA and endothelin-1 (ET-1) receptors in SK-N-
MC cells do not activate ERKs unless the EGFR is co-ex-
pressed, although each GPCR is functional as evidenced
by their ability to increase intracellular [Ca2+]. In the pres-
Figure 9
Effect of antagonists to the insulin receptor (HNMPA-(AM)3)
or the PDGF receptor (tyrosphostin-9) on ERK phosphoryla-
tion and tyrosine phosphorylation of the δ -OR by DSLET.
C6-δ -OR cells were serum-starved overnight prior to expo-
sure to DSLET (1 µM for 5 minutes). In some instances,
DSLET exposure was performed in cells pre-treated with
HNMPA-(AM)3 (100 µM) or tyrosphostin-9 (100 µM) 60
minutes prior to the δ -OR agonist. After agonist exposure,
cell lysates were prepared and divided into aliquots for the
analysis of ERK phosphorylation or tyrosine phosphorylation
of the δ -OR. The δ -OR was immunoprecipitated as
described in the methods section using the appropriate anti-
bodies. Tyrosine phosphorylation of the δ -OR or ERK phos-
phorylation was determined by SDS PAGE, followed by
immunoblotting of proteins onto nitrocellulose. Immunopos-
itive bands corresponding to the tyrosine-phosphorylated
form of the δ -OR (hatched bars) or ERK phosphorylation
(open bars) were quantified using the MCID system. Band
intensities are expressed graphically as: grain density ×  band
area - [region of detection (ROD)] ×  pixel. Data points rep-
resent the mean ± SEM of three experiments. *p ≤  0.05 com-
pared to untreated samples as determined by ANOVA and
the Tukey post-hoc test.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/5
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ence of the EGFR, ligand activation of LPA and ET-1 recep-
tors did not increase EGFR phosphorylation even though
both the LPA and ET-1 receptors stimulated ERK activity
by 10-fold over basal [27]. Specifically, key protein inter-
mediates may be physically associated with endogenous
RTKs in HEK-293 cells, and therefore, down-regulation of
the EGFR may negatively affect ERK phosphorylation by
opioids. To examine this, we induced significant down-
regulation of EGFR density and function by exposing δ -
OR-HEK-293 cells to 100 ng/ml EGF for 24 hours. Func-
tionally, these cells are no longer capable of activating
ERK 1 or 2 in response to 10 ng/ml EGF (Figure), whereas
this concentration produces a strong effect in non-pre-
treated cells. Conversely, DSLET-mediated ERK phospho-
rylation is actually greater in chronically-treated EGF
cultures to that observed in cells not previously exposed to
high EGF concentrations. This may represent a compensa-
tory effect to counteract the loss of function of an impor-
tant growth factor receptor. In a similar experiment, a 24-
hour exposure to DSLET (10 µM) induced significant δ -
OR down-regulation and an almost complete loss of DS-
LET-mediated ERK phosphorylation. MAP kinase activa-
tion by a 5 minute exposure to EGF was unaffected by δ -
OR down-regulation. These results, taken together, sug-
gest that GPCRs and RTKs can act as independent regula-
tors of MAP kinase cascades, although interactions
between the two receptor types may exist in certain cases.
In conclusion, we report that the δ -OR agonist, DSLET, in-
duces significant ERK activation in the absence of any in-
crease in phosphorylation of the co-expressed EGFR in
HEK-293 cells. HEK-293 cells endogenously express the
EGFR, and EGF produces robust ERK activation concomi-
tant with EGFR tyrosine phosphorylation. Immunopre-
cipitation studies showed that the δ -OR becomes tyrosine
phosphorylated after exposure to DSLET, but not to EGF.
These studies were repeated in δ -OR-transfected C6 glio-
ma cells, which do not express the EGFR. In these cells,
DSLET was still able to induce ERK activation. Additional
studies showed that the two RTKs, which are present in C6
glioma cells, IRs and PDGFRs, had no apparent role on
ERK activation by a δ -opioid agonist. Furthermore, induc-
ing down-regulation of either the EGFR or δ -OR by chron-
ic agonist treatment has little effect on ERK activation by
the other receptor in HEK-293 cells, suggesting that these
pathways are distinct. These results demonstrate that opi-
oid-mediated ERK activation occurs independently of
EGFR transphosphorylation, and that the tyrosine-phos-
phorylated δ -OR may serve as the primary scaffold.
Materials and Methods
Drugs and compounds
All chemicals used for these studies were of reagent grade
and obtained from the following sources. The Src inhibi-
tor, 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo
[3,4-d]pyrimidine (PP1), was purchased from Calbio-
chem (La Jolla, CA). The EGFR antagonist, AG1478 (4-(3-
chloroanilino)-6,7-dimethoxyquinazoline), the insulin
receptor antagonist, hydroxy-2-napthalenylmethylphos-
phonic acid-tris acetoxymethylester (HNMPA-(AM)3),
and the PDGFR antagonist, tyrosphostin, 9 were pur-
chased from Biomol (Plymouth Meeting, PA). The opioid
agonist, [D-Ser-Leu-enkephalin-Thr (DSLET), was re-
ceived from the National Institute of Drug Abuse (NIDA,
Baltimore, MD) and the antagonist, naltrindole, was pur-
chased from Research Biochemicals, Inc., (Natick, MA).
Pertussis toxin (PTX) was purchased from Sigma Chemi-
cal Co. (St. Louis, MO). Insulin was obtained from Uni-
versity Hospital of New York University and PDGF was
purchased from Biomol (Plymouth Meeting, PA). All oth-
er compounds were obtained from the sources listed un-
der the individual methods.
Cell transfection and culture
C6 glioma cells were stably transfected with the cDNA en-
coding the epitope-tagged (FLAG) mouse δ -opioid recep-
tor (C6-δ OR) and were created in our laboratory using the
Flp-In transfection method. HEK-293 cells were transfect-
ed, in house, with the cDNA encoding the FLAG-tagged
wild-type (HEK-δ OR) mouse δ -OR. Complete methods
for the stable transfection of HEK-293 cells to express the
wild type receptor can be found in a previous report [13].
Both cell lines were seeded in 6-well dishes at an initial
cell density of 1 ×  106 cells/well and were maintained in
Dulbecco's modified Eagle's medium (DMEM; Gibco-
BRL) supplemented with 2 mM L-glutamine, 5% fetal bo-
vine serum (FBS) (Gemini Bio-Products, Calabasas, CA),
and 100 µg/ml gentamycin sulfate (Gemini Bio-Products,
Calabasas, CA). Selection pressure was maintained by the
presence of 1 mg/ml G418 sulfate (Life Technologies,
Inc.) in the culture media, which was kept at 37°C in 7%
CO2/humidified air and was changed every 3–4 days.
Cell treatment and the immunoprecipitation (IP) of the δ -
OR or the EGFR
C6-δ OR or HEK-δ OR cells were not treated until they
reached 80–90% confluency. Relative levels of receptor
expression were continuously measured among cell types
by radioligand binding assays [28] to insure that all cells
used expressed 1–2 pmol/mg protein of 3H-diprenor-
phine (3H-DIPR; 3H-DIPR, 54 Ci/mmol, Amersham; 0.1–
1.5 nM) binding. Sixteen hours before the addition of
drugs, the culture medium was removed and replaced by
fresh serum-free DMEM. All inhibitors/antagonists were
added at least thirty minutes before opioid agonists or
EGF. After a five-minute opioid or EGF incubation, the
cell monolayers were rinsed twice with ice cold phos-
phate-buffered saline (PBS), and the cells were solubilized
by the addition of 300 µl of solubilization buffer (50 mM
Tris-HCl/Base (pH7.4), 1 % Triton X-100, 10% glycerol,BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/5
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1.5 mM MgCl2, 1.0 mM CaCl2, 300 mMNaCI, 1 mM
NaVO3, and the protease inhibitors leupeptin (100 µg/
ml), PMSF (100 µM), and aprotinin (100 µg/ml)) for 60
minutes at +4°C. Soluble proteins were isolated by centrif-
ugation at 30,000 g for ten minutes at +4°C. Primary cell
lysates were analyzed for protein concentration using the
Bio-Rad method. A mouse monoclonal antibody raised
against the FLAG-epitope (Flag-M1 antibody (2–5 µg/µl),
Sigma Chemical, St. Louis, Mo.) was used to immunopre-
cipitate the tagged δ -OR from the cell lysates, and a
murine anti-EGFR antibody ((5 µg/µl) clone LA22; Up-
state Biotechnology, Lake Placid, NY) was used to immu-
noprecipitate out the EGFR. Antibodies to the insulin (C-
19 epitope-β  subunit; rabbit polyclonal IgG (5 µg/µl))
and PDGF receptor (C-20 epitope; rabbit polyclonal IgG
(5 µg/µl)) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Immunoprecipitation of all receptor
types was performed using magnetic Dynabeads (Dynal
Bioscience, Lake Success, NY) coated with anti-mouse or
anti-rabbit IgG and used according to the manufacturer's
instructions. Proteins were prepared for SDS-PAGE by
boiling them in 2 ×  Lammeli's sample buffer and stored at
-70°C until used.
Immunoblotting for the presence of phosphorylated MAPK 
(ERK1/2) and phosphorylated tyrosines
SDS PAGE and immunoblotting (IB) were performed fol-
lowing the methods contained in a previous report [11],
and all procedures were performed at room temperature
unless otherwise noted. Proteins (5–20 µg/lane) were sep-
arated by using 10–20% acrylamide gels, and electroblot-
ted onto nitrocellulose membranes. Non-specific binding
sites were blocked by incubating the nitrocellulose for 60
minutes in blocking buffer (25 mM Tris-HCl/Base, 150
mM NaCl, 0.05% Tween-20, and 3% nonfat dry milk).
For the identification of the activated form of ERK (pERK)
from primary cell lysates, we used an antibody raised
against pERK-1/2 (1:5,000 dilution in blocking solution,
Santa Cruz Biotechnology, Santa Cruz, CA). Total MAPK
levels were quantified using the ERK-1 antibody (C-16
epitope; 1:5,000 dilution in blocking solution), which
was also obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). Mouse monoclonal antibodies raised against
phosphorylated tyrosines (clone PY20 (1:2,000 dilution),
Santa Cruz Biotechnology, Santa Cruz, CA) were used to
identify tyrosine phosphorylated EGFR or δ -ORs. Incuba-
tion with all primary antibodies was carried on overnight
at +4°C. Membranes were then incubated for 60 minutes
in the presence of a goat-anti-mouse secondary antibody
linked to horseradish-peroxidase (1:2,000) at room tem-
perature. Immunoreactive proteins were visualized using
a horseradish peroxidase-sensitive ECL chemiluminescent
Western blotting (WB) kit (Pierce).
Data Analysis and statistical methods
Radioligand binding curves (to determine kD and Bmax)
were generated, and all regression analyses were per-
formed using the LIGAND curve-fitting program [29].
Graphs were produced using Sigmaplot for Windows (ver-
sion 4.0). Images of immunoreactive bands were captured
on x-ray film and analyzed using the MCID morphomet-
ric system (Imaging Research Inc., Ontario, Canada). All
immunochemical assays were performed at least three
times, although results from a single experiment are
sometimes shown for clarity. One-way and two-way anal-
yses of variance (ANOVA) and the post-hoc Tukey test
were used for multiple comparisons at a minimum signif-
icance level of p ≤  0.05. Student's t-test was substituted for
the ANOVA for simple two-sample tests at the same signif-
icance level. Statistical data are expressed as mean ± stand-
ard error (SE) of the indicated number of observations.
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